Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $54.50.

A number of equities research analysts have issued reports on OMCL shares. Wall Street Zen cut shares of Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings raised Omnicell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, February 9th. Piper Sandler restated an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Benchmark lifted their price target on Omnicell from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Finally, Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a research report on Monday, February 9th.

Omnicell Trading Up 1.4%

Shares of OMCL stock opened at $41.93 on Friday. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.00. The company has a market cap of $1.88 billion, a PE ratio of 1,048.51, a price-to-earnings-growth ratio of 1.45 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $45.16 and its two-hundred day moving average is $37.85.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm had revenue of $313.98 million for the quarter, compared to the consensus estimate of $313.36 million. During the same period in the prior year, the company posted $0.60 earnings per share. Omnicell’s quarterly revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities analysts predict that Omnicell will post 1.09 EPS for the current year.

Insider Buying and Selling

In related news, EVP Corey J. Manley sold 6,106 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. This represents a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.52% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mercer Global Advisors Inc. ADV raised its position in shares of Omnicell by 51.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,573 shares of the company’s stock valued at $615,000 after buying an additional 4,599 shares during the last quarter. State of Tennessee Department of Treasury increased its stake in Omnicell by 15.1% during the fourth quarter. State of Tennessee Department of Treasury now owns 26,504 shares of the company’s stock valued at $1,285,000 after acquiring an additional 3,470 shares during the period. EP Wealth Advisors LLC acquired a new position in Omnicell in the 4th quarter valued at approximately $307,000. Fuller & Thaler Asset Management Inc. acquired a new position in Omnicell in the 4th quarter valued at approximately $610,000. Finally, Empowered Funds LLC bought a new stake in shares of Omnicell in the 4th quarter worth approximately $274,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.